Goyal Parveen, Goyal Kumud, Vijaya Kumar Sengodan Gurusamy, Singh Ajit, Katare Om Prakash, Mishra Dina Nath
Department of Pharmaceutics, Lord Shiva College of Pharmacy, Near Civil Hospital, Post Box No. 63 Sirsa-125055, Haryana, India.
Acta Pharm. 2005 Mar;55(1):1-25.
Liposomes have been widely investigated since 1970 as drug carriers for improving the delivery of therapeutic agents to specific sites in the body. As a result, numerous improvements have been made, thus making this technology potentially useful for the treatment of certain diseases in the clinics. The success of liposomes as drug carriers has been reflected in a number of liposome-based formulations, which are commercially available or are currently undergoing clinical trials. The current pharmaceutical preparations of liposome-based therapeutic systems mainly result from our understanding of lipid-drug interactions and liposome disposition mechanisms. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes that can be targeted on tissues, cells or intracellular compartments with or without expression of target recognition molecules on liposome membranes. This review is mainly focused on the diseases that have attracted most attention with respect to liposomal drug delivery and have therefore yielded most progress, namely cancer, antibacterial and antifungal disorders. In addition, increased gene transfer efficiencies could be obtained by appropriate selection of the gene transfer vector and mode of delivery.
自1970年以来，脂质体作为药物载体已被广泛研究，用于改善治疗药物向体内特定部位的递送。因此，已经取得了许多改进，从而使这项技术在临床上治疗某些疾病方面具有潜在的用途。脂质体作为药物载体的成功体现在许多基于脂质体的制剂中，这些制剂已上市或正在进行临床试验。目前基于脂质体的治疗系统的药物制剂主要源于我们对脂质-药物相互作用和脂质体处置机制的理解。现在可以将从脂质体药物递送系统的临床应用中获得的见解整合起来，以设计能够靶向组织、细胞或细胞内区室的脂质体，无论脂质体膜上是否表达靶标识别分子。本综述主要关注在脂质体药物递送方面最受关注并因此取得最大进展的疾病，即癌症、抗菌和抗真菌疾病。此外，通过适当选择基因传递载体和递送方式，可以提高基因传递效率。
